
Specialty PBM | YTD Jul25 vs. Jul25 – Dec25

Specialty Rx Transition & Cost Analysis



1. Grandfathering of specialty Rx drugs ended after 10/31/2025. (2 Stelara, 6 Tremfya, 9 Humira and 6 Skyrizi utilizers during this period.)
2. One Stelara utilizer was converted to a low-cost biosimilar (Yesintek) and the other is no longer on specialty therapy.
3. Of the six Tremfya utilizers, one transitioned to Yesintek; two requested Tremfya and were denied PA with redirection to alternatives (including Yesintek); one requested Cosentyx and was denied PA with redirection to Yesintek; and two are no longer on specialty therapy.
4. The plan currently has no brand Humira utilizers. Two members are no longer on the plan and the other 7 are regularly filling a Humira biosimilar.
5. Three of the Skyrizi members are still utilizing while the other three are no longer on a specialty medication.